A macromolecules containing a metal and a use thereof as a catalyst are disclosed. The macromolecules containing a metal may be obtained by causing a ligand to react with a zinc compound or a cobalt compound. The ligand has an imidazole group that is bonded to a macromolecule via a linker. The metal-containing macromolecules are highly active as a catalyst, stable, and easy to recover and reuse.

A macromolecules containing a metal and a use thereof as a catalyst are disclosed. The macromolecules containing a metal may be obtained by causing a ligand to react with a zinc compound or a cobalt compound. The ligand has an imidazole group that is bonded to a macromolecule via a linker. The metal-containing macromolecules are highly active as a catalyst, stable, and easy to recover and reuse.

The present disclosure relates to an organometallic framework modified using a compound having a hydroxyl group (—OH), a catalyst for a hydrogenation reaction including the same, and a method of manufacturing the same. The catalyst according to the present disclosure has high activity to the hydrogenation reaction even at a low temperature of 30 to 40° C., thus making low-grade waste heat usable.

The present disclosure relates to an organometallic framework modified using a compound having a hydroxyl group (—OH), a catalyst for a hydrogenation reaction including the same, and a method of manufacturing the same. The catalyst according to the present disclosure has high activity to the hydrogenation reaction even at a low temperature of 30 to 40° C., thus making low-grade waste heat usable.

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I). ##STR00001##

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I). ##STR00001##

The present invention relates to a selective reduction of specific aldehydes and ketones to their corresponding alcohols.

The present invention relates to a selective reduction of specific aldehydes and ketones to their corresponding alcohols.

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I).

##STR00001##

The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I).

##STR00001##